Abstract:The Philadelphia chromosome is formed by a balanced, reciprocal translocation that pairs sequences from BCR on Chromosome 22 with sequences from ABL on Chromosome 9, resulting in the production of the constitutively active tyrosine kinase (TK) BCR-ABL. Depending on the location of the breakpoint within BCR, three different sizes of BCR-ABL may form, each associated with distinct clinical sequelae. Previous studies identified a functional domain within the BCR sequences preserved by the more-indolent forms of BCR-ABL (i.e., p210 and p230) that demonstrates a constitutive Rho guanine nucleotide exchange factor (RhoGEF) activity. Using the structurally derived S509A mutation, which does not affect TK activity but abrogates RhoGEF signaling, we, subsequently, showed that this feature regulates leukemia progression in mice. The RhoGEF domain was recently reported to contain two missense mutations (F547L and T654K) in a chronic myelogenous leukemia (CML) blast crisis (BC) patient, suggesting that it may play a role in human disease as well. To evaluate the clinical significance of this region, we, therefore, examined p210 BCR-ABL constructs containing these clinically derived RhoGEF mutations (CDRMs), both in isolation and in combination, using a murine bone marrow transplant (mBMT) model of CML. The mutations did not destabilize p210 BCR-ABL expression or TK activity but decreased RhoGEF signaling. Relative to mice transplanted with wild-type (WT) p210 BCR-ABL, those that received the CDRMs exhibited an earlier onset of disease, frequently developing previously unseen dermatologic involvement or myeloid sarcomas, but demonstrated significantly increased survival in an additive manner [Fig. 1]. While mice transplanted with WT p210 BCR-ABL exhibited neutrophilia that progresses to a less-differentiated phenotype at death, disease in the CDRM mice was characterized by eosinophilia and monocytosis with no maturation arrest. The most likely cause of death in mice transplanted with WT p210 BCR-ABL is widespread hematogenous involvement of the lungs resulting in acute respiratory distress. In contrast, mice receiving the CDRMs demonstrated pulmonary involvement which was limited to the bronchovascular bundles or subpleural space. This is consistent with a switch to lymphatogenous spread, likely secondary to skewed differentiation, and it implies an alternate cause(s) of death. To help determine the mechanism responsible for the observed differences in differentiation and maturation arrest, we next studied the CDRMs in vitro using the 32Dcl3 murine myeloid precursor cell line. A growing body of evidence suggests that the DNA damage response can affect lineage restriction in myeloid cells; it is also well-established that the accumulation of DNA damage is necessary for progression to BC. Accordingly, the CDRMs were associated with the restoration of p53 activation and the G1/S cell cycle checkpoint relative to WT p210 BCR-ABL. This suggests that the RhoGEF domain may be responsible for the suppression of the DNA damage response. Because the mBMT phenotype associated with the S509A mutation was distinct from that of the CDRMs, it may indicate that this capability is mediated by some functionality yet to be described. Importantly, the CDRMs were also associated with increased Src family kinase activity, which is thought to be a major mechanism of BCR-ABL-independent TK inhibitor resistance and minimal residual disease. Collectively, these results suggest that the BCR-ABL RhoGEF domain can influence disease progression and response to treatment in human leukemia. Disclosures No relevant conflicts of interest to declare.

Breakpoint Cluster Region Gene Product-Related Domain of N-Chimaerin. Discrimination Between Rac-binding and GTPase-activating Residues by Mutational Analysis.

Balanced Rac1 activity controls formation and maintenance of neuromuscular acetylcholine receptor clusters.

Identification of the role of a cysteine-rich region of PC6B by determining the enzymatic characteristics of its mutants

Ferm Domain Containing Protein 7 Interacts With The Rho Gdp Dissociation Inhibitor And Specifically Activates Rac1 Signaling

Characterization of the Interactions Between the Small GTPase Cdc42 and Its GTPase-activating Proteins and Putative Effectors

Cross GTPase-activating Protein (crossgap)/vilse Links the Roundabout Receptor to Rac to Regulate Midline Repulsion

A Fragment Activity Assay Reveals the Key Residues of TBC1D15 GTPase-activating Protein (GAP) in Chiloscyllium Plagiosum

A bivalent dissectional analysis of the high-affinity interactions between Cdc42 and the Cdc42/Rac interactive binding domains of signaling kinases in Candida albicans.

Implication of Rac1 GTPase in molecular and cellular mitochondrial functions

The Tiam1 Guanine Nucleotide Exchange Factor is Auto-Inhibited by Its Pleckstrin Homology Coiled-Coil Extension Domain.

Assay of Cdc42, Rac, and Rho GTPase Activation by Affinity Methods

Examination of Clinically-Derived p210 BCR/ABL Rhogef Mutations in a Murine Bone Marrow Transplantation Model of CML

IQGAP1 Interaction with RHO Family Proteins Revisited

Structural Basis for the Specific Recognition of RhoA by the Dual GTPase-activating Protein ARAP3*

Structural basis for selective targeting of Rac subfamily GTPases by a bacterial effector protein

Structure-function analysis of RAMP1 by alanine mutagenesis

A Novel Crumbs3 Isoform Regulates Cell Division and Ciliogenesis Via Importin Β Interactions

Loss function of Bcr mutation causes gastrointestinal dysmotility and brain developmental defects

Identification of a Novel Guanine Nucleotide Exchange Factor for the Rho GTPase

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia

A single residue can modify target-binding affinity and activity of the functional domain of the Rho-subfamily GDP dissociation inhibitors.